A detailed history of Northern Trust Corp transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 691,206 shares of CRBU stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
691,206
Previous 710,129 2.66%
Holding current value
$1.17 Million
Previous $1.16 Million 15.72%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.56 - $2.73 $29,519 - $51,659
-18,923 Reduced 2.66%
691,206 $1.35 Million
Q2 2024

Aug 14, 2024

SELL
$1.62 - $5.05 $39,100 - $121,886
-24,136 Reduced 3.29%
710,129 $1.16 Million
Q1 2024

May 14, 2024

SELL
$4.82 - $8.26 $111,327 - $190,781
-23,097 Reduced 3.05%
734,265 $3.77 Million
Q4 2023

Feb 13, 2024

BUY
$3.58 - $6.25 $251,305 - $438,731
70,197 Added 10.22%
757,362 $4.34 Million
Q3 2023

Nov 13, 2023

BUY
$4.08 - $8.14 $633,138 - $1.26 Million
155,181 Added 29.17%
687,165 $3.28 Million
Q2 2023

Aug 11, 2023

BUY
$4.04 - $5.47 $12,035 - $16,295
2,979 Added 0.56%
531,984 $2.26 Million
Q1 2023

May 15, 2023

SELL
$4.3 - $7.78 $23,572 - $42,649
-5,482 Reduced 1.03%
529,005 $2.81 Million
Q4 2022

Feb 13, 2023

BUY
$5.57 - $11.01 $63,102 - $124,732
11,329 Added 2.17%
534,487 $3.36 Million
Q3 2022

Nov 14, 2022

BUY
$5.34 - $12.79 $390,236 - $934,667
73,078 Added 16.24%
523,158 $5.52 Million
Q2 2022

Aug 12, 2022

BUY
$5.1 - $9.74 $236,180 - $451,059
46,310 Added 11.47%
450,080 $2.44 Million
Q1 2022

May 13, 2022

BUY
$8.42 - $15.32 $1.85 Million - $3.37 Million
219,683 Added 119.34%
403,770 $3.71 Million
Q4 2021

Feb 08, 2022

BUY
$14.59 - $23.26 $161,744 - $257,860
11,086 Added 6.41%
184,087 $2.78 Million
Q3 2021

Nov 15, 2021

BUY
$15.75 - $30.29 $2.72 Million - $5.24 Million
173,001 New
173,001 $4.13 Million

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $103M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.